Elevance Health Inc

UnitedHealth Group is shifting its Medicare Advantage strategy to prioritize profitability over membership expansion, expecting 2026 enrollment to decline by approximately 1.1 million members due to targeted exits from unprofitable plans. Medicare margins are now expected to finish the year above 3%, reflecting tighter benefit design, pricing actions, and a more favorable membership mix, while the company expects Medicare medical cost trends to come below the initial estimate of near 10%. UnitedHealth's consolidated medical care ratio improved to 86.7% in the second quarter from 89.4% a year ago, and the company raised its 2026 adjusted EPS outlook to $19.50-$20. The Zacks Consensus Estimate for UnitedHealth's 2026 earnings is pegged at $19.69 per share, implying 20.4% growth from the year-ago period, and the stock currently carries a Zacks Rank #1 (Strong Buy).

McKesson reported second-quarter revenues of $105.4 billion, up 7.7% year over year and 1.2% above analyst expectations, while its stock remained flat at $868.87. Among the 39 healthcare providers and services stocks tracked, aggregate revenues beat consensus by 1.7% and next-quarter guidance came in 1.6% above estimates, yet the group's average share price fell 1.2% since earnings. CVS Health posted the best quarter with revenues of $106.1 billion, up 7.3% and 6.7% above expectations, but its stock dropped 9.1% to $94.90. AdaptHealth was the weakest performer, missing revenue estimates by 12.6% with revenues of $740.3 million and issuing significantly lower full-year revenue and EBITDA guidance, sending its stock down 46.2% to $5.83. Elevance Health reported flat revenues of $49.83 billion, beating estimates by 2.5%, but lost 469,000 customers and saw its stock fall 7.4% to $395.18, while Quest Diagnostics grew revenues 10.2% to $3.04 billion and its stock rose 12.6% to $236.32.

The healthcare sector gained about 2.45% in July, outperforming the broader S&P 500 which slipped around 0.12%. Regeneron Pharmaceuticals was the biggest winner, climbing 22.08%, followed by DexCom which gained 21.19% after its Q2 earnings beat and raised full-year guidance, and Baxter International which advanced 20.61%. Moderna was the biggest detractor, dropping 24.39%, while Intuitive Surgical fell 12.19% and managed-care insurers Humana, Elevance Health, and Centene also finished among the weakest performers. Earnings-driven gains in pharmaceuticals and medtech contrasted with weakness in managed-care insurers and vaccine makers.

Elevance Health's large Medicaid division is posting a negative operating margin that management forecasts at approximately -1.75% for the full year, calling 2026 the trough year for the segment. The company is exiting the D.C. Medicaid market and expects to leave additional markets over the next 12 to 18 months where sustainable profits are not in sight. While the Commercial and Medicare Advantage segments perform well, the unprofitable Medicaid business pressures overall profitability and challenges the growth narrative supporting the stock's valuation. The company's ability to deliver at least 12% adjusted EPS growth in 2027 hinges on whether the Medicaid margin improves or market exits continue.

The S&P 500 closed at a six-week high on Wednesday, rising 0.38% as a softer-than-expected June producer price report and strong earnings from ASML outweighed a rout in semiconductor stocks. The Dow Jones Industrial Average added 0.29%, while the Nasdaq 100 slipped 0.28% under pressure from chipmakers. June final-demand producer prices rose 5.5% year-over-year, below the 6.2% consensus, and the July Empire manufacturing survey jumped to 15.6, well above the 9.2 estimate. Apple surged more than 4% after China approved the rollout of its generative artificial intelligence feature, leading gains among the Magnificent Seven, while ASML’s results underscored robust AI-driven chip demand. However, the iShares Semiconductor ETF fell over 2%, with Western Digital down more than 8% and Micron Technology off more than 6%. Health insurers also declined after Elevance Health tumbled more than 8% on guidance that disappointed relative to its second-quarter beat. PayPal soared over 17% on a report that Stripe and Advent International made a joint $53 billion takeover offer.

SpaceX shares fell for a fourth straight session, dipping below their $135 initial public offering price for the first time. Apple rose about 4% to a fresh high after its Apple Intelligence cleared a major regulatory hurdle in China, lifting partner shares Alibaba by 5% and Baidu by 2%. Memory stocks pulled back sharply, with Micron, Seagate, and Western Digital each down around 8% and Sandisk tumbling more than 11% on fears of intensifying competition from Chinese chipmaker ChangXin Memory Technologies. Cava gained 5.5% after Morgan Stanley upgraded the fast-casual chain to overweight, calling it one of the strongest fundamental stories in restaurants. Lionsgate jumped more than 6% on a Reuters report that the studio is exploring a sale and has drawn interest from France's Bollore Group and Banijay Group. Progressive fell more than 7% after reporting a 31% drop in June income and a combined ratio rising to 90%, dragging Allstate down 4%, AON down less than 1%, and Travelers down almost 2%. Lucid Group rebounded 19% after denying reports of bankruptcy or take-private talks, saying it has sufficient liquidity into next year. BlackRock jumped more than 7% on better-than-expected adjusted earnings of $13.91 per share versus an LSEG estimate of $12.59. Pentair tumbled more than 17% after preliminary second-quarter adjusted earnings of $1.12 a share missed the $1.48 FactSet consensus. Morgan Stanley edged up after record quarterly revenue and profit, with earnings of $3.46 per share beating the $2.94 estimate. PayPal surged 17% on a Reuters report that Stripe and Advent offered to buy it for $53 billion, or $60.50 per share. Elevance Health fell 10% despite second-quarter revenue above consensus and raised full-year earnings guidance. Bank of New York Mellon rose nearly 3% after an earnings and revenue beat, with double-digit revenue growth now expected in 2026 but higher expenses also forecast.

Several major companies made significant premarket moves following earnings reports and deal news. BlackRock jumped more than 4.5% after reporting adjusted earnings of $13.91 per share, beating the LSEG estimate of $12.59. PayPal surged 19% after Reuters reported that Stripe and Advent offered to buy the digital payments platform for $53 billion, pricing it at $60.50 per share. ASML rose 3% after the Dutch semiconductor-equipment maker beat quarterly estimates and raised its full-year sales outlook, now forecasting a gross margin between 54 and 56%, up from a prior range of 51 to 53%. Morgan Stanley gained 1.5% on record quarterly revenues and profits, with earnings of $3.46 per share versus the $2.94 expected. In contrast, Pentair tumbled more than 14% after issuing preliminary second-quarter adjusted earnings guidance of $1.12 per share, well below the $1.48 FactSet consensus. Johnson & Johnson slipped more than 1% despite posting adjusted earnings of $2.90 per share on revenue of $25.31 billion, slightly above analyst forecasts. Elevance Health fell 7% even though second-quarter revenue topped estimates and it raised full-year earnings guidance. IBM recovered more than 1% after suffering its worst day on record Tuesday with a 25% plunge on disappointing preliminary results. M&T Bank rose 2% on earnings of $5.32 per share, exceeding the FactSet consensus of $4.66, while Bank of New York Mellon slipped 1% despite beating estimates, as it flagged higher future expenses.

Elevance Health's second-quarter 2026 results triggered a broad selloff in managed-care stocks as margin pressure in its Health Benefits segment overshadowed better-than-expected headline numbers. Elevance shares fell 6.7% in premarket trading after adjusted operating margin in the segment dropped to 3.6% from 5.0% a year earlier, with operating profit nearly halving due to lagging Medicaid reimbursement rates and a Medicare Advantage repositioning. UnitedHealth Group declined 2.7% ahead of its own quarterly report, while pure-play Medicaid insurer Molina Healthcare dropped as much as 9%, the steepest decline among major peers. Humana fell roughly 1.7%, Centene lost 4.9%, and CVS Health was down 2.3%. Elevance posted revenue of $50.47 billion, up 2.1% year-on-year and beating consensus by 3.9%, and adjusted earnings per share of $7.45, about 20% above the $6.21 estimate, while raising full-year adjusted EPS guidance to at least $27.00, but the core insurance performance raised concerns that Medicaid margin deterioration could be sector-wide.

Elevance Health is set to report second-quarter 2026 results on July 15, with the Zacks Consensus Estimate pegging earnings at $6.18 per share on revenues of $48.45 billion, implying a 30.1% drop in earnings and a 2% revenue decline year over year. The Health Benefits segment's operating income is expected to plunge 34.7%, while the benefit expense ratio is seen rising to 89.4 from 88.9 a year ago, further pressuring profitability. Membership declines are also anticipated, with Commercial Individual memberships forecast to fall 10% and Medicaid memberships down 5.8%, though Commercial Fee-based memberships are projected to grow 1.9%. Despite these challenges, Elevance has beaten earnings estimates in three of the last four quarters with an average surprise of 10.6%, and the stock carries a Zacks Rank of 2.

Analyst forecasts pointing to lower quarterly earnings of $6.18 per share and decreasing revenue expectations have put Elevance Health in focus, prompting investors to reassess the stock. Despite the cautious earnings outlook, Elevance Health's share price has climbed 33.61% over the past 90 days and delivered a 24.75% total shareholder return over the last year. The most followed narrative pegs fair value at about $418.67 against a last close of $416.23, suggesting only a modest gap between price and projected worth while still framing the stock as materially undervalued in longer term cash flow terms. Strategic investments in digital consumer engagement and Carelon's diversified health services are expected to accelerate revenue growth and provide higher-margin, recurring income streams.

Elevance Health has filed a lawsuit against the Centers for Medicare & Medicaid Services, alleging the agency unfairly recalculated Medicare Advantage Star Ratings for competitor Clover Health after finalization, costing Elevance an estimated $115 million in quality bonus payments. The suit claims CMS applied a different standard to Clover Health while denying similar relief to other insurers, creating an uneven competitive landscape. Elevance is asking the court to overturn the decision and restore a consistent ratings process for all Medicare Advantage insurers. The outcome could affect bonus payments and competitive positioning across the industry, with federal spending on Medicare Advantage quality bonuses expected to top $13 billion this year.

A new study from the Elevance Health Public Policy Institute finds that arbitration awards for certain planned medical procedures under the No Surprises Act are often tens to hundreds of times higher than typical in-network payment rates. The research examined more than 7,300 payment disputes involving scheduled services such as spine surgery, plastic surgery, and colonoscopy, where providers won nearly 90 percent of disputed claim lines. The average independent dispute resolution award was nearly $40,000, compared with benchmark rates ranging from approximately $645 to $1,600, and the median award was more than 50 times the median in-network contracted rate for the same service in the same market. Awards for these procedures increased 43 percent between 2024 and 2025. The study raises concerns that the dispute resolution process is being used for scheduled services in ways that diverge from the law's original intent, contributing to higher healthcare costs for employers and families.

UBS analysts say hospitals could build a more durable competitive advantage from artificial intelligence than health insurers, even as AI becomes a core operating layer across healthcare. Analyst A.J. Rice notes that while managed-care companies like UnitedHealth Group, Elevance Health, Humana, Cigna, and Centene are deploying AI for claims processing, prior authorization, and customer service, those efficiency gains are highly replicable and likely to be competed away through pricing or benefit enhancements. In contrast, large for-profit hospital operators such as HCA Healthcare, Tenet Healthcare, and Universal Health Services are using AI for revenue cycle management, denial appeals, and staffing optimization, and may maintain a multiyear lead over slower-moving nonprofit systems. UBS highlights that Universal Health Services generated approximately $50 million in annualized additional revenue from an AI coding platform, while HCA is using AI to fight claim denials and optimize nurse staffing with a Palantir-built platform. The report concludes that AI will improve profitability unevenly, with hospitals better positioned to retain gains and expand margins over time.